PPARα Ligands and Clinical Trials: Cardiovascular Risk Reduction with Fibrates

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 8, Issue 4, 2001, Pages 195-201

  Robins, Sander J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CELL RECEPTOR; CHOLESTEROL; LIGAND; TRANSCRIPTION FACTOR; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG;

BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; METABOLISM; REVIEW; RISK FACTOR; ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG INDUCED DISEASE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; INSULIN RESISTANCE; PRIMARY PREVENTION; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 0034741947     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182670100800403     Document Type: Article

References (28)

1. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19: 792–802.
2. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237–1245.
3. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995; 92: 1779–1785.
4. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, deFaire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849–853.
5. Syvanne M, Nieminen MS, Frick MH, Kauma H, Majahalme S, Virtanen V, et al Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998; 98: 1993–1999.
6. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001; 357: 905–910.
7. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. BMJ 1971; 4: 767–775.
8. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: A secondary prevention trial using clofibrate. BMJ 1971; 4: 775–784.
9. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069–1118.
10. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–381.
11. Heady JA, Morris JN, Oliver MF. WHO clofibrate/cholesterol trial: Clarifications. Lancet 1992; 340: 1405–1406.
12. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405–418.
13. Manninen V, Elo O, Frick H, et al Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641–651.
14. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85: 37–45.
15. The BIP Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21–27.
16. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, et al For the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993; 71: 909–915.
17. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–418.
18. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deewania PC, Schaefer EJ, et al Relation of gemfibrozil treatment and lipid levels with major coronary events: V-HIT A randomized controlled trial. JAMA 2001; 284: 1585–1591.
19. Rubins HB, Robins SJ, Collins D For the Veterans Affairs, Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. The Veterans Affairs High-Density Lipoprotein Intervention Trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol 1996; 78: 572–575.
20. Kanal WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 1979; 2: 120–126.
21. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128: 389–401.
22. Haffner SM, Lehto S, Ronnemaa T, Pyoralia Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.
23. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–957.
24. Lempiainen P, Mykkanen L, Pyorala K, Laakso M, Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100: 123–128.
25. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation 2000; 101: 975–980.
26. Meigs JB, Nathan DM, Wilson PWF, Cupples A, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998; 128: 524–533.
27. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med 1999; 159: 2661–2667.
28. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893–1900.